<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">INO</journal-id>
<journal-id journal-id-type="hwp">spino</journal-id>
<journal-title>InnovAiT</journal-title>
<issn pub-type="ppub">1755-7380</issn>
<issn pub-type="epub">1755-7399</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1755738013488283</article-id>
<article-id pub-id-type="publisher-id">10.1177_1755738013488283</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>AKT</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>AKT question relating to thiazolidinediones</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Nandakumar</surname><given-names>Michael</given-names><prefix>Dr</prefix></name></contrib>
</contrib-group>
<aff id="aff1-1755738013488283">GP, Fairfields Practice, Nottingham</aff>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>6</volume>
<issue>4</issue>
<fpage>213</fpage>
<lpage>213</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">Royal College of General Practitioners</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<sec id="sec1-1755738013488283"><title>Free response question</title>
<p>The following table shows the use of thiazolidinediones and risk of bladder cancer among cases of bladder cancer and matched controls.</p>
<p><bold>In this analysis, how many patients with bladder cancer had EVER used pioglitazone OR rosiglitazone? Type in a SINGLE numerical answer in the box.</bold>
<table-wrap id="table1-1755738013488283" position="float">
<graphic alternate-form-of="table1-1755738013488283" xlink:href="10.1177_1755738013488283-table1.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th>Use of thiazolidinedione</th><th>No (%) of cases (n = 376)</th><th>No (%) of controls (n = 6699)</th><th>Crude ratio (95% CI)</th><th>Adjusted rate ratio (95% CI)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Never use of any thiazolidinedione</td>
<td>319 (84.8)</td>
<td>5856 (87.4)</td>
<td>1.00 (reference)</td>
<td>1.00 (reference)</td>
</tr>
<tr>
<td>Exclusive ever use of pioglitazone</td>
<td>19 (5.1)</td>
<td>191 (2.9)</td>
<td>1.87 (1.13 to 3.09)</td>
<td>1.83 (1.10 to 3.05)</td>
</tr>
<tr>
<td>Exclusive ever use of rosiglitazone</td>
<td>36 (9.6)</td>
<td>596 (8.9)</td>
<td>1.16 (0.79 to 1.69)</td>
<td>1.14 (0.78 to 1.68)</td>
</tr>
<tr>
<td>Ever use of both pioglitazone  and rosiglitazone</td>
<td>2 (0.5)</td>
<td>56 (0.8)</td>
<td>0.74 (0.18 to 3.08)</td>
<td>0.78 (0.18 to 3.29)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1755738013488283"><p><italic>Reproduced from Azoulay, L., Yin, H., Filion, K. B., Assayag, J., Majdan, A., Pollak, M. N., &amp; Suissa, S. (2012). BMJ, 344, e3645, with permission from BMJ Publishing Group Ltd.</italic></p></fn></table-wrap-foot>
</table-wrap>
</p>
<p>Answer DOI: <related-article ext-link-type="doi" id="related-article1-1755738013488283" related-article-type="companion" xlink:href="10.1177/1755738013488284" xlink:type="simple">10.1177/1755738013488284</related-article></p>
</sec>
</body>
</article>